Analytical Data
-
基因名
FGFR-1
-
简介
FGFR-1 alpha is a tyrosine-protein kinase receptor for fibroblast growth factor that is critical in embryonic development, cell proliferation, differentiation, and migration. GnRH is essential for mesodermal patterning, axial organization, skeletogenesis, and nervous system development. FGFR-1 beta (IIIc) Protein, Human (HEK293, His-Avi) is the recombinant human-derived FGFR-1 beta, expressed by HEK293 , with C-Avi, C-His labeled tag.
- Application
-
生物活性
1.Immobilized Anti-FGFR1 Anitibody, hFc Tag at 2 μg/mL (100 μl/Well)on the plate. Dose response curve for Human FGFR1 beta (Illc), His Tag with the EC50 of ≤ 0.34 μg/mL determined by ELISA. 2.Immobilized Human FGFR1 beta (IIIc) at 0.5 μg/mL (100 μL/Well) on the plate. Dose response curve for Anti-FGFR1 Antibody with the ED50 of 0.3177 μg/mL determined by ELISA. Immobilized Human FGFR1 beta (IIIc) at 0.5 μg/mL (100 μL/Well) on the plate. Dose response curve for Anti-FGFR1 Antibody with the ED50 of 0.3177 μg/mL determined by ELISA.
-
别名
Fibroblast growth factor receptor 1; FGFR-1; BFGFR; bFGF-R-1; FLT-2; CD331;
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 95% as determined by reducing SDS-PAGE.
-
蛋白编号
P11362-7
-
表达区间
K158-T355
-
氨基酸序列
KMEKKLHAVPAAKTVKFKCPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLT
-
蛋白长度
Partial
-
分子量
40-55 kDa.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibroblast growth factor receptor 1 (FGFR-1) is a crucial receptor that plays vital roles in various biological processes, including cellular proliferation, differentiation, and survival. Research on FGFR-1 has gained momentum due to its significant implications in developmental biology and pathophysiology, particularly in cancer. Abnormal FGFR-1 signaling has been linked to various malignancies, including breast, lung, and bladder cancers, making it a target for therapeutic intervention. The development of recombinant FGFR-1 proteins has been instrumental in elucidating its structural and functional properties. By generating these proteins through recombinant DNA technology, researchers can produce pure and functional FGFR-1 to study its interactions with ligands, downstream signaling pathways, and the effects of mutations associated with cancer. Additionally, understanding the molecular mechanisms governing FGFR-1 activity can aid in the design of FGFR-targeted therapies, such as selective inhibitors and antibodies, offering potential treatment strategies for FGFR-1-driven tumors. The advancement of FGFR-1 recombinant protein studies has also provided insights into the receptor's role in tissue regeneration and repair, highlighting its importance beyond oncology. As research continues to uncover the complexities of FGFR-1 signaling, it remains a key focus in both basic and translational research aimed at improving disease outcomes through targeted molecular therapies.
